Immunotoxicity studies on the insecticide 2-((1-(4-Phenoxyphenoxy)propan-2yl)oxy)pyridine (MPEP) in Hsd:Harlan Sprague Dawley SD rats
Victor J. Johnson, Stefanie C.M. Burleson, Michael I. Luster, Gary R. Burleson, Barry McIntyre, Karen Cimon, Reshan Fernando, James Blake, Crystal L. Johnson, Dori R. Germolec
Publication
Abstract
To address public health programs for vector control, initiated by the recent spread of Zika virus, 2-((1-(4-Phenoxyphenoxy)propan-2-yl)oxy)pyridine (MPEP), a broad-spectrum insect growth regulator (IGR) with insecticidal activity, is increasingly being used. While considered relatively safe for humans under normal conditions, limited toxicology data are available. Current studies were undertaken to address the data gap regarding potential immunotoxicity of MPEP, with particular emphasis on host resistance to viral infection. Hsd:Harlan Sprague Dawley SD® rats were treated for 28 days by oral gavage with doses of 0, 62.5, 125, 250 or 500 mg/kg/day of MPEP in corn oil. There was a dose-dependent increase in liver weights which is consistent with the liver playing a dominant role in MPEP metabolism. However, no histological correlates were observed. Following treatment, rats were subjected to a battery of immune tests as well as influenza virus infection to provide a comprehensive assessment of immune function and host resistance. While several of the immune tests showed minor exposure-related changes, evidenced by negative dose-response trends, most did not show significant differences in any of the MPEP treatment groups relative to the vehicle control. Most notable was a negative trend in pulmonary mononuclear cell phagocytosis with increasing dose of MPEP. Furthermore, MPEP treatment had no effect on the ability of rats to clear the influenza virus nor the T-dependent IgM and IgG antibody response to the virus. Overall, under the conditions of the current studies, the lack of findings in the disease resistance studies and minimal effects in the immunotoxicity studies suggest that there was little impact on immune function in HSD rats following MPEP exposure.
Study Data
Study Tables - 28-day Rat Immunotox Study
- I01 – Animal Removal Summary (90 KB)
- I02 - Animal Removals (312 KB)
- I03 - Growth Curve (2 MB)
- I03C - Growth Curve (2 MB)
- I04 - Mean Body Weight Summary (362 KB)
- I04G - Mean Body Weight Gain (297 KB)
- I05 - Clinical Observations Summary (144 KB)
- M03 - Peripheral Blood Leukocyte Cell Differential (34 KB)
- M04 - Hematology (35 KB)
- M06 - Spleen Immunophenotyping (36 KB)
- M07 - TDAR SRBC Spleen AFC (32 KB)
- M08 - Serum IgM Antibody Titers to the T-Dependent Antigen Sheep Erythrocytes (30 KB)
- M09 - Serum Antibody Concentrations for the T-Dependent Antigen Keyhole Limpet Hemocyanin KLH (33 KB)
- M11 - Spleen Cell Proliferative Response to Anti-CD3 Stimulation (34 KB)
- M12 - Cytotoxic T Cell Activity (31 KB)
- M14 - Functional Activity of the Mononuclear Phagocytic System (33 KB)
- M15 - Natural Killer Cell Activity (30 KB)
- M19 - TDAR SRBC ELISpot (32 KB)
- PA02 - Incidence Rates of Neoplasms by Anatomic Site (127 KB)
- PA03 - Incidence Rates of Non-Neoplastic Lesions by Anatomic Site (136 KB)
- PA05 - Incidence Rates of Neoplasms by Anatomic Site (Systemic Lesions Abridged) (127 KB)
- PA06 - Organ Weights Summary (45 KB)
- PA10X - Statistical Analysis of Non-Neoplastic Lesions (156 KB)
- PA14 - Individual Animal Pathology Data (1 MB)
- PA18 - Incidence Rates of Non-Neoplastic Lesions by Anatomic Site with Average Severity Grades (137 KB)
- PA46 - Summary of Gross Pathology (771 KB)
Study Tables - Rat Influenza Host Resistance Study
- I01 - Animal Removal Summary (74 KB)
- I02 - Animal Removals (1 MB)
- I03 - Growth Curve (1 MB)
- I03C - Growth Curve (1 MB)
- I04 - Mean Body Weight Summary (209 KB)
- I04G - Mean Body Weight Gain (185 KB)
- I05 - Clinical Observations Summary (117 KB)
- M13 - Infectious Viral Titers in Lung Homogenates (35 KB)
- M16 - Influenza-Specific IgM and IgG Antibody Titers (35 KB)
- PA06 - Organ Weights Summary (163 KB)
Individual Animal Data - 28-day Rat Immunotox Study
- Individual Animal Anti - SRBC IgM ELISpot Data (9 KB)
- Individual Animal Anti - SRBC Serum IgM Antibody Response Data (7 KB)
- Individual Animal Body Weight Data (75 KB)
- Individual Animal Calculated Endpoints Anti - SRBC ELISpot Data (9 KB)
- Individual Animal Calculated Endpoints CytotoxicTCell Data (10 KB)
- Individual Animal Calculated Endpoints Natural Killer Cell Activity Data (10 KB)
- Individual Animal Calculated Endpoints Pulmonary Phagocytosis Data (9 KB)
- Individual Animal Calculated Endpoints Spleen Anti - CD3 Proliferation Data (10 KB)
- Individual Animal Calculated Endpoints Spleen Antibody Forming Cell Response Data (9 KB)
- Individual Animal Calculated Endpoints Spleen Immunophenotyping Data (31 KB)
- Individual Animal Clinical Observations Data (410 KB)
- Individual Animal Cytotoxic T Cell Activity Data (14 KB)
- Individual Animal Gross Pathology Data (64 KB)
- Individual Animal Hematology Data (15 KB)
- Individual Animal KLH TDAR Data (19 KB)
- Individual Animal Natural Killer Cell Activity Data (14 KB)
- Individual Animal Organ Weight Data (30 KB)
- Individual Animal Pulmonary Phagocytosis Data (10 KB)
- Individual Animal Removal Reasons Data (19 KB)
- Individual Animal Spleen Anti - CD3 Proliferation Data (12 KB)
- Individual Animal Spleen Antibody Forming Cell Response Data (9 KB)
- Individual Animal Spleen Immunophenotyping Data (13 KB)
Individual Animal Data - Rat Influenza Host Resistance Study
- Individual Animal Body Weight Data (33 KB)
- Individual Animal Calculated Endpoints Influenza Titer Data (16 KB)
- Individual Animal Clinical Observations Data (134 KB)
- Individual Animal Influenza Elisa Data (14 KB)
- Individual Animal Influenza Titer Data (20 KB)
- Individual Animal Organ Weight Data (19 KB)
- Individual Animal Removal Reasons Data (14 KB)